LucenceINSIGHT™ is a multi-cancer early detection (MCED) test that screens for the signal of 50 cancers through a simple blood draw. It leverages proprietary technology to amplify and identify signs of ctDNA and viruses in the bloodstream. The advanced sequencing analysis predicts signal localization.
LucenceINSIGHT™ is a multi-cancer early detection tool that screens for the signals of up to 50 cancers in a simple blood draw.
It leverages proprietary technology to amplify and identify signs of ctDNA and viruses in the bloodstream. The advanced sequencing analysis predicts signal localization.
The result is cross examined with machine-learning to study the cancer signal profile. Utilizing data from the analysis, the test reports a presence or absence of a cancer signal. A localization signal is also derived and used to predict up to 2 sites where the cancer signal might have originated from (“Predicted Signal Localization”). The report will present the result as Predicted Signal Localization, with an accuracy of 88%.
AmpliMarkTM Upgrade (Lucence Mirror Barcodes)
Lucence's ultrasensitive amplicon-based enrichment chemistry offers high sensitivity and specificity for sequencing circulating tumor DNA, with low error rate achieved through mirror barcoding.
LucenceINSIGHT™ is based on a proprietary amplicon-based technology to screen for the signal of cancer with a specificity of 99.2%.
The test detects cancer-associated alterations circulating in blood. Advanced sequence analysis predicts the site of origin. The report will present your result as Areas of Concern, with an accuracy of 90%.
Early Detection Leads to Better Outcomes
LucenceINSIGHT™ is recommended in conjunction with existing screening tools for:
LucenceINSIGHT™ is recommended for use in conjunction with existing screening tools for individuals without a personal history of cancer.
Retrospective study shown at ASCO 2023:
Real-world experience shown at ESMO Asia 2023:
There are 50 cancer types covered by LucenceINSIGHT™ PLUS. LucenceINSIGHT™ covers the 12 cancers highlighted in orange.
Breast, Gastrointestinal stromal tumour (GIST), Lung (Small cell lung cancer, Non-small cell lung cancer, Lung Neuroendocrine Tumour), Bile Duct, Colorectal, Nasopharyngeal, Liver, Pancreas, Cervical, Prostate.
LucenceINSIGHT™ + Acute Myeloid Leukemia, Bladder, Endometrium, Eye, Head and Neck, Kidney, Lymphoplasmacytic Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Oropharynx, Skin and Stomach.
Clinical Assessment
Blood Tests
Urine Tests
CARDIAC SCREEN
Cytology
IMAGING
Clinical Assessment
Blood Tests
Urine Tests
Stool Test
CARDIAC SCREEN
Cytology
IMAGING
Clinical Assessment
Blood Tests
Urine Tests
Stool Test
CARDIAC SCREEN
Cytology
IMAGING
PLUS CHOOSE 2 OF
Clinical Assessment
Blood Tests
Urine Tests
Stool Test
CARDIAC SCREEN
Cytology
IMAGING
PLUS CHOOSE 3 OF
SCOPES
